{"protocolSection":{"identificationModule":{"nctId":"NCT03003962","orgStudyIdInfo":{"id":"D419AC00002"},"secondaryIdInfos":[{"id":"2018-001375-21","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","officialTitle":"A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-01-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-10-27","type":"ACTUAL"},"completionDateStruct":{"date":"2026-06-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2016-12-15","studyFirstSubmitQcDate":"2016-12-22","studyFirstPostDateStruct":{"date":"2016-12-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2023-10-23","resultsFirstSubmitQcDate":"2023-12-22","resultsFirstPostDateStruct":{"date":"2023-12-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-02","lastUpdatePostDateStruct":{"date":"2025-09-03","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type and with PD-L1 high expression (PEARL)","detailedDescription":"Patients with stage IV NSCLC will be randomized in a 1:1 ratio to 2 treatment arms (durvalumab or SOC therapy). The dual primary objectives of this study are to assess the efficacy of durvalumab versus SoC in terms of OS (Overall Survival) in all randomized patients and in patients who are at low risk of EM (early mortality)"},"conditionsModule":{"conditions":["Non Small Cell Lung Carcinoma NSCLC"],"keywords":["NSCLC","PD-L1","Durvalumab (MEDI4736)","OS"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":669,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1: Durvalumab","type":"EXPERIMENTAL","description":"Anti-PD-L1 monoclonal Antibody monotherapy","interventionNames":["Drug: Durvalumab (MEDI4736)"]},{"label":"Arm 2: Standard of Care","type":"ACTIVE_COMPARATOR","description":"Standard of Care Platinum-Based chemotherapy","interventionNames":["Drug: Paclitaxel + carboplatin","Drug: Gemcitabine + cisplatin","Drug: Gemcitabine + carboplatin","Drug: Pemetrexed + cisplatin","Drug: Pemetrexed + carboplatin"]}],"interventions":[{"type":"DRUG","name":"Durvalumab (MEDI4736)","description":"Anti-PD-L1 monoclonal Antibody monotherapy","armGroupLabels":["Arm 1: Durvalumab"]},{"type":"DRUG","name":"Paclitaxel + carboplatin","description":"Chemotherapy Agents","armGroupLabels":["Arm 2: Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]},{"type":"DRUG","name":"Gemcitabine + cisplatin","description":"Chemotherapy Agents","armGroupLabels":["Arm 2: Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]},{"type":"DRUG","name":"Gemcitabine + carboplatin","description":"Chemotherapy Agents","armGroupLabels":["Arm 2: Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]},{"type":"DRUG","name":"Pemetrexed + cisplatin","description":"Chemotherapy Agent","armGroupLabels":["Arm 2: Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]},{"type":"DRUG","name":"Pemetrexed + carboplatin","description":"Chemotherapy Agent","armGroupLabels":["Arm 2: Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.","timeFrame":"From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months [data cut-off (DCO) 27 October 2022]"},{"measure":"OS in Participants With LREM","description":"OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.","timeFrame":"From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)"}],"secondaryOutcomes":[{"measure":"OS in PD-L1 TC >= 50% Analysis Set","description":"OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.","timeFrame":"From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)"},{"measure":"OS in PD-L1 TC >= 50% LREM Analysis Set","description":"OS is defined as the time from the date of randomization until death due to ay cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.","timeFrame":"From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)"},{"measure":"Progression Free Survival (PFS) Based on Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"The PFS (per RECIST 1.1) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1). Progression of disease per RECIST 1.1, when either 1 of the criteria met: Target lesion (TL): at least a 20% increase in the sum of diameters of TLs, for reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Non-target lesion (NTL): Unequivocal progression of existing NTLs. It may be due to an important progression in 1 lesion only or in several lesions. In all cases the progression must be clinically significant for the physician to consider changing (or stopping) therapy. New lesions: the presence of 1 or more new lesions was assessed as progression.","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months DCO 27 October 2022)"},{"measure":"PFS Based on Investigator Assessment According to RECIST 1.1 in LREM Analysis Set","description":"The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)"},{"measure":"PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% Analysis Set","description":"The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)"},{"measure":"PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% LREM Analysis Set","description":"The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)"},{"measure":"Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment","description":"ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions (TLs). Any pathological lymph nodes selected as TLs had a reduction in short axis to \\< 10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)"},{"measure":"ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 25% LREM Analysis Set","description":"ORR (per RECIST 1.1 using Investigator assessments)was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)"},{"measure":"ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% Analysis Set","description":"ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)"},{"measure":"ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% LREM Analysis Set","description":"ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)"},{"measure":"Duration of Response (DoR) as Per RECIST 1.1 Using Investigator Assessment","description":"DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)"},{"measure":"DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=25% LREM Analysis Set","description":"DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)"},{"measure":"DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% Analysis Set","description":"DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)"},{"measure":"DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% LREM Analysis Set","description":"DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)"},{"measure":"Alive and Progression-Free at 12 Months (APF12)","description":"The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.","timeFrame":"From date of randomization until 12 months"},{"measure":"APF12 in PD-L1 TC >= 25% LREM Analysis Set","description":"The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.","timeFrame":"From date of randomization until 12 months"},{"measure":"APF12 in PD-L1 TC >= 50% Analysis Set","description":"The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.","timeFrame":"From date of randomization until 12 months"},{"measure":"APF12 in PD-L1 TC >= 50% LREM Analysis Set","description":"The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.","timeFrame":"From date of randomization until 12 months"},{"measure":"Time From Randomization to Second Progression (PFS2)","description":"PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.","timeFrame":"Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)"},{"measure":"PFS2 in PD-L1 TC >= 25% LREM Analysis Set","description":"PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.","timeFrame":"Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)"},{"measure":"PFS2 in PD-L1 TC >= 50% Analysis Set","description":"PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.","timeFrame":"Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)"},{"measure":"PFS2 in PD-L1 TC >= 50% LREM Analysis Set","description":"PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.","timeFrame":"Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)"},{"measure":"OS at 18 Months","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.","timeFrame":"From date of randomization till 18 months."},{"measure":"OS at 18 Months in PD-L1 TC > = 25% LREM Analysis Set","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.","timeFrame":"From date of randomization till 18 months"},{"measure":"OS at 18 Months in PD-L1 TC >= 50% Analysis Set","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.","timeFrame":"From date of randomization till 18 months"},{"measure":"OS at 18 Months in PD-L1 TC >= 50% LREM Analysis Set","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.","timeFrame":"From date of randomization till 18 months"},{"measure":"OS at 24 Months","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.","timeFrame":"From date of randomization till 24 months"},{"measure":"OS at 24 Months in PD-L1 TC > = 25% LREM Analysis Set","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.","timeFrame":"From date of randomization till 24 months"},{"measure":"OS at 24 Months in PD-L1 TC >= 50% Analysis Set","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.","timeFrame":"From date of randomization till 24 months"},{"measure":"OS at 24 Months in PD-L1 TC >= 50% LREM Analysis Set","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.","timeFrame":"From date of randomization till 24 months"},{"measure":"Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire Version 3 (QLQ-C30)","description":"The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual. An outcome variable consisted of a score from 0 to 100. Higher scores on the global health status and functioning scales indicate better health status/function, but higher scores on symptom scales/items represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The mixed model repeated measures (MMRM) analysis of EORTC QLQ-C30 considered all data from baseline to PD or 12 months.","timeFrame":"Baseline and 12 months"},{"measure":"Change From Baseline in EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set","description":"The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual. An outcome variable consisted of a score from 0 to 100. Higher scores on the global health status and functioning scales indicate better health status/function, but higher scores on symptom scales/items represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-C30 considered all data from baseline to PD or 12 months.","timeFrame":"Baseline and 12 months"},{"measure":"Time to Deterioration of EORTC QLQ-C30","description":"Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful deterioration (a decrease in the function scales or the global health status/ health-related quality of life \\[HRQoL\\] from baseline of ≥10) that was confirmed at a subsequent visit or death in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual.","timeFrame":"From randomization until date of first symptom deterioration that is confirmed, assessed up to a maximum of approximately 69 months (DCO 27 October 2022)"},{"measure":"Time to Deterioration of EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set","description":"Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual.","timeFrame":"From randomization until date of first symptom deterioration that is confirmed, assessed up to a maximum of approximately 69 months (DCO 27 October 2022)"},{"measure":"Change From Baseline in EORTC 13-Item Lung Cancer Quality of Life Questionnaire (QLQ-LC13)","description":"The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication. An outcome variable consisted of a score from 0 to 100. Higher scores on symptom scales represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-LC13 considered all data from baseline to PD or 12 months.","timeFrame":"Baseline and 12 months"},{"measure":"Change From Baseline in EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set","description":"The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication. An outcome variable consisted of a score from 0 to 100. Higher scores on symptom scales represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-LC13 considered all data from baseline to PD or 12 months.","timeFrame":"Baseline and 12 months"},{"measure":"Time to Deterioration of EORTC QLQ-LC13","description":"Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful symptom deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication.","timeFrame":"From randomization until date of first symptom deterioration that is confirmed, assessed up to maximum of approximately 69 months (DCO 27 October 2022)"},{"measure":"Time to Deterioration of EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set","description":"Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful symptom deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication.","timeFrame":"From randomization until date of first symptom deterioration that is confirmed, assessed up to maximum of approximately 69 months (DCO 27 October 2022)"},{"measure":"Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"ECOG performance status was assessed at the times specified based on the following and scored as 0: fully active: able to carry out all usual activities without restrictions. 1: Restricted in strenuous activity, but ambulatory and able to carry out any work activities; up and about more than 50% of waking hours. 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 4: Completely disabled; unable to carry out any self-care and totally confined to bed or chair and 5: death. Data for only participants with restricted activity has been reported.","timeFrame":"From Baseline and until follow-up period of 57 months"},{"measure":"Number of Participants With ECOG Performance Status in PD-L1 TC >=25% LREM Analysis Set","description":"ECOG performance status was assessed at the times specified based on the following and scored as 0: fully active: able to carry out all usual activities without restrictions. 1: Restricted in strenuous activity, but ambulatory and able to carry out any work activities; up and about more than 50% of waking hours. 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 4: Completely disabled; unable to carry out any self-care and totally confined to bed or chair and 5: death. Data for only participants with restricted activity has been reported.","timeFrame":"From Baseline and until follow-up period of 57 months"},{"measure":"Percentage of Participants With Antidrug Antibody (ADA) Response to Durvalumab","description":"Treatment-emergent ADA positive was defined as either treatment-induced or treatment-boosted ADA. Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following study drug administration. Persistently positive was defined as positive at least 2 post-baseline assessments with at least 16 weeks between the first and last positive assessment or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.","timeFrame":"Up to 24 weeks"},{"measure":"Percentage of Participants With ADA Response to Durvalumab in LREM Analysis Set","description":"Treatment-emergent ADA positive was defined as either treatment-induced or treatment-boosted ADA. Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following study drug administration. Persistently positive was defined as positive at least 2 post-baseline assessments with at least 16 weeks between the first and last positive assessment or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.","timeFrame":"Up to 24 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Aged at least 18 years\n* Documented evidence of Stage IV NSCLC\n* No sensitizing EGFR mutation and ALK rearrangement\n* PD-L1 high expression\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nExclusion Criteria:\n\n* Prior chemotherapy or any other systemic therapy for advanced NSCLC\n* Prior exposure to immune-mediated therapy, including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies, excluding therapeutic anticancer vaccines\n* Brain metastases or spinal cord compression unless the patient is stable and off steroids for at least 14 days prior to start of study treatment\n* Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant\n* Active or prior documented autoimmune or inflammatory disorders (e.g., colitis or Crohn's disease\\]","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Research Site","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Research Site","city":"Box Hill","zip":"3128","country":"Australia","geoPoint":{"lat":-37.81887,"lon":145.12545}},{"facility":"Research Site","city":"Gosford","zip":"2250","country":"Australia","geoPoint":{"lat":-33.4244,"lon":151.34399}},{"facility":"Research Site","city":"Kogarah","zip":"2217","country":"Australia","geoPoint":{"lat":-33.9681,"lon":151.13564}},{"facility":"Research Site","city":"St Leonards","zip":"2065","country":"Australia","geoPoint":{"lat":-33.82344,"lon":151.19836}},{"facility":"Research Site","city":"Beijing","zip":"100032","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Research Site","city":"Beijing","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Research Site","city":"Beijing","zip":"100853","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Research Site","city":"Bengbu","zip":"233004","country":"China","geoPoint":{"lat":32.94083,"lon":117.36083}},{"facility":"Research Site","city":"Changchun","zip":"130000","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Research Site","city":"Changsha","zip":"410013","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"Research Site","city":"Chengdu","zip":"610041","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Research Site","city":"Chongqing","zip":"400030","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Research Site","city":"Guangzhou","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Research Site","city":"Guangzhou","zip":"510095","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Research Site","city":"Haikou","zip":"570311","country":"China","geoPoint":{"lat":20.03421,"lon":110.34651}},{"facility":"Research Site","city":"Hangzhou","zip":"310003","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Research Site","city":"Hangzhou","zip":"310006","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Research Site","city":"Hangzhou","zip":"310009","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Research Site","city":"Hangzhou","zip":"310022","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Research Site","city":"Jinan","zip":"250031","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Research Site","city":"Linhai","zip":"317000","country":"China","geoPoint":{"lat":22.8836,"lon":107.264}},{"facility":"Research Site","city":"Nanchang","zip":"330006","country":"China","geoPoint":{"lat":28.68396,"lon":115.85306}},{"facility":"Research Site","city":"Nanjing","zip":"210009","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"Research Site","city":"Ningbo","zip":"315010","country":"China","geoPoint":{"lat":29.87819,"lon":121.54945}},{"facility":"Research Site","city":"Shanghai","zip":"200030","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Research Site","city":"Shenyang","zip":"110042","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"Research Site","city":"Shijiazhuang","zip":"050020","country":"China","geoPoint":{"lat":38.04139,"lon":114.47861}},{"facility":"Research Site","city":"Ürümqi","zip":"830000","country":"China","geoPoint":{"lat":43.80096,"lon":87.60046}},{"facility":"Research Site","city":"Ürümqi","zip":"830054","country":"China","geoPoint":{"lat":43.80096,"lon":87.60046}},{"facility":"Research Site","city":"Wanzhou","zip":"404000","country":"China","geoPoint":{"lat":30.76451,"lon":108.39586}},{"facility":"Research Site","city":"Wenzhou","zip":"CN-325000","country":"China","geoPoint":{"lat":27.99942,"lon":120.66682}},{"facility":"Research Site","city":"Wuhan","zip":"430010","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Research Site","city":"Wuhan","zip":"430022","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Research Site","city":"Wuhan","zip":"430030","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Research Site","city":"Xi'an","zip":"710038","country":"China","geoPoint":{"lat":34.25833,"lon":108.92861}},{"facility":"Research Site","city":"Xi'an","zip":"710061","country":"China","geoPoint":{"lat":34.25833,"lon":108.92861}},{"facility":"Research Site","city":"Zhengzhou","zip":"450008","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"Research Site","city":"Zhuhai","zip":"519099","country":"China","geoPoint":{"lat":22.27694,"lon":113.56778}},{"facility":"Research Site","city":"Budapest","zip":"1083","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Budapest","zip":"1121","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Budapest","zip":"1122","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Deszk","zip":"6772","country":"Hungary","geoPoint":{"lat":46.21802,"lon":20.24322}},{"facility":"Research Site","city":"Farkasgyepü","zip":"8582","country":"Hungary"},{"facility":"Research Site","city":"Gyöngyös - Mátraháza","zip":"3200","country":"Hungary"},{"facility":"Research Site","city":"Székesfehérvár","zip":"8000","country":"Hungary","geoPoint":{"lat":47.18995,"lon":18.41034}},{"facility":"Research Site","city":"Törökbálint","zip":"2045","country":"Hungary","geoPoint":{"lat":47.42931,"lon":18.91356}},{"facility":"Research Site","city":"Almelo","zip":"7600SZ","country":"Netherlands","geoPoint":{"lat":52.35667,"lon":6.6625}},{"facility":"Research Site","city":"Bialystok","zip":"15-027","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"Research Site","city":"Grudziądz","zip":"86-300","country":"Poland","geoPoint":{"lat":53.48411,"lon":18.75366}},{"facility":"Research Site","city":"Koszalin","zip":"75-581","country":"Poland","geoPoint":{"lat":54.19438,"lon":16.17222}},{"facility":"Research Site","city":"Lublin","zip":"20-090","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Research Site","city":"Mrozy","zip":"05-320","country":"Poland","geoPoint":{"lat":52.16609,"lon":21.80263}},{"facility":"Research Site","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Research Site","city":"Wroclaw","zip":"53-413","country":"Poland","geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"Research Site","city":"Arkhangelsk","zip":"163045","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"facility":"Research Site","city":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Novosibirsk","zip":"630108","country":"Russia","geoPoint":{"lat":55.02259,"lon":82.93175}},{"facility":"Research Site","city":"Omsk","zip":"644013","country":"Russia","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"Research Site","city":"Rostov-on-Don","zip":"344037","country":"Russia","geoPoint":{"lat":47.21997,"lon":39.70769}},{"facility":"Research Site","city":"Saint Petersburg","zip":"194291","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Saint Petersburg","zip":"196603","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Saint Petersburg","zip":"197183","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Saint Petersburg","zip":"197342","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Volgograd","zip":"400138","country":"Russia","geoPoint":{"lat":48.71378,"lon":44.4976}},{"facility":"Research Site","city":"Changwon-si","zip":"51353","country":"South Korea"},{"facility":"Research Site","city":"Cheongju-si","zip":"28644","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"Research Site","city":"Daegu","zip":"42415","country":"South Korea","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Research Site","city":"Incheon","zip":"21565","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Research Site","city":"Jinju","zip":"660-702","country":"South Korea","geoPoint":{"lat":35.19278,"lon":128.08472}},{"facility":"Research Site","city":"Seoul","zip":"03722","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Suwon","zip":"16499","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Research Site","city":"Taichung","zip":"402","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Research Site","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Research Site","city":"Taipei","zip":"112","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Research Site","city":"Taipei","zip":"235","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Research Site","city":"Bangkok","zip":"10330","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Research Site","city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Research Site","city":"Muang","zip":"50200","country":"Thailand"},{"facility":"Research Site","city":"Songkhla","zip":"90110","country":"Thailand","geoPoint":{"lat":7.19882,"lon":100.5951}},{"facility":"Research Site","city":"Ankara","zip":"06490","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Research Site","city":"Istanbul","zip":"34030","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Research Site","city":"Istanbul","zip":"34854","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Research Site","city":"Malatya","zip":"44100","country":"Turkey (Türkiye)","geoPoint":{"lat":38.35018,"lon":38.31667}},{"facility":"Research Site","city":"Pamukkale","zip":"20070","country":"Turkey (Türkiye)","geoPoint":{"lat":37.91644,"lon":29.11729}},{"facility":"Research Site","city":"Can Tho","zip":"900000","country":"Vietnam","geoPoint":{"lat":10.03711,"lon":105.78825}},{"facility":"Research Site","city":"Hanoi","zip":"100000","country":"Vietnam","geoPoint":{"lat":21.0245,"lon":105.84117}},{"facility":"Research Site","city":"Hanoi","zip":"10000","country":"Vietnam","geoPoint":{"lat":21.0245,"lon":105.84117}},{"facility":"Research Site","city":"Ho Chi Minh City","zip":"10000","country":"Vietnam","geoPoint":{"lat":10.82302,"lon":106.62965}},{"facility":"Research Site","city":"Ho Chi Minh City","zip":"700000","country":"Vietnam","geoPoint":{"lat":10.82302,"lon":106.62965}},{"facility":"Research Site","city":"Ho Chi Minh City","zip":"70000","country":"Vietnam","geoPoint":{"lat":10.82302,"lon":106.62965}}]},"referencesModule":{"seeAlsoLinks":[{"label":"CSR Synopsis","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419AC00002&amp;attachmentIdentifier=78e650f3-53a9-42f0-8ee7-98654cae7412&amp;fileName=d419ac00002_CSR_Synopsis.pdf&amp;versionIdentifier="},{"label":"CSP","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419AC00002&amp;attachmentIdentifier=e22a0ee4-f267-4a3e-8427-8d623ae5b200&amp;fileName=D419AC00002_Protocol.pdf&amp;versionIdentifier="},{"label":"SAP","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419AC00002&amp;attachmentIdentifier=32bffb61-41f6-4de8-9d93-66b17672af32&amp;fileName=d419ac00002_SAP.pdf&amp;versionIdentifier="}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","infoTypes":["STUDY_PROTOCOL","SAP"],"timeFrame":"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","accessCriteria":"When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","url":"https://astrazenecagroup-dt.pharmacm.com/DT/Home"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Overall 3075 participants were screened at 98 centers in 12 countries. A total of 669 participants were randomized in a 1:1 ratio. Of those, 549 participants fulfilled the criteria for PD-L1 TC \\>= 25% low risk of early mortality (LREM).","recruitmentDetails":"This Phase III, open-label, multi-center study was conducted in participants with programmed cell death ligand 1 (PD-L1)- tumor cell (TC) \\>= 25% advanced non small-cell lung cancer (NSCLC) at 85 centers in 10 countries (China, Russia, Hungary, Poland, South Korea, Vietnam, Turkey, Australia, Taiwan, and Thailand). First participant was enrolled on 02 January 2017 and last participant was enrolled on 25 January 2019.","groups":[{"id":"FG000","title":"Durvalumab","description":"Participants received durvalumab 20 milligram (mg)/kilogram (kg) via intravenous (IV) infusion every 4 weeks (Q4W) until documented disease progression (PD) or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"FG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based standard of care (SoC) as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/ square meter (m\\^2) and carboplatin area under the plasma concentration curve (AUC) 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","comment":"Randomized","achievements":[{"groupId":"FG000","numSubjects":"335"},{"groupId":"FG001","numSubjects":"334"}]},{"type":"PD L1 TC ≥ 25% LREM Analysis Set","achievements":[{"groupId":"FG000","numSubjects":"278"},{"groupId":"FG001","numSubjects":"271"}]},{"type":"PD L1 TC ≥ 50% Analysis Set","achievements":[{"groupId":"FG000","numSubjects":"247"},{"groupId":"FG001","numSubjects":"246"}]},{"type":"PD L1 TC ≥ 50% LREM Analysis Set","achievements":[{"groupId":"FG000","numSubjects":"207"},{"groupId":"FG001","numSubjects":"199"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"334"},{"groupId":"FG001","numSubjects":"334"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"17"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"274"},{"groupId":"FG001","numSubjects":"277"}]},{"type":"Participants ongoing at DCO","reasons":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"40"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The Full analysis set (FAS) included all randomized participants.","groups":[{"id":"BG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"BG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"335"},{"groupId":"BG001","value":"334"},{"groupId":"BG002","value":"669"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.7","spread":"9.73"},{"groupId":"BG001","value":"61.9","spread":"8.71"},{"groupId":"BG002","value":"61.3","spread":"9.25"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"132"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"268"},{"groupId":"BG001","value":"269"},{"groupId":"BG002","value":"537"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"134"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"262"},{"groupId":"BG001","value":"273"},{"groupId":"BG002","value":"535"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"8"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"333"},{"groupId":"BG001","value":"328"},{"groupId":"BG002","value":"661"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months [data cut-off (DCO) 27 October 2022]","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"334"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","lowerLimit":"12.2","upperLimit":"16.9"},{"groupId":"OG001","value":"12.8","lowerLimit":"10.1","upperLimit":"14.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","nonInferiorityComment":"The analysis was performed using the stratified log-rank test, adjusting for PD-L1 expression (TC 25% to 49% versus \\>= 50%) and histology and smoking status (squamous vs. non-squamous + never smoker vs.\n\nnon-squamous + former/current smoker) and using the rank tests of association approach.","pValue":"0.037","statisticalMethod":"Stratified Log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.706","ciUpperLimit":"0.989","estimateComment":"The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model"}]},{"type":"PRIMARY","title":"OS in Participants With LREM","description":"OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.","populationDescription":"The PD-L1 TC \\>= 25% LREM analysis set included participants identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"271"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","lowerLimit":"12.6","upperLimit":"17.2"},{"groupId":"OG001","value":"15.0","lowerLimit":"13.1","upperLimit":"16.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","nonInferiorityComment":"The analysis was performed using the stratified log-rank test, adjusting for PD-L1 expression (TC 25% to 49% versus \\>= 50%) and histology and smoking status (squamous vs. non-squamous + never smoker vs.\n\nnon-squamous + former/current smoker) and using the rank tests of association approach.","pValue":"0.628","statisticalMethod":"Stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.793","ciUpperLimit":"1.151","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model."}]},{"type":"SECONDARY","title":"OS in PD-L1 TC >= 50% Analysis Set","description":"OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.","populationDescription":"The PD-L1 TC \\>= 50% analysis set included the subset of participants in the FAS whose PD-L1 expression status was PD-L1 TC \\>= 50% as defined by the VENTANA PD-L1 (SP263) assay.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"246"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","lowerLimit":"12.0","upperLimit":"17.7"},{"groupId":"OG001","value":"11.8","lowerLimit":"9.8","upperLimit":"14.7"}]}]}]},{"type":"SECONDARY","title":"OS in PD-L1 TC >= 50% LREM Analysis Set","description":"OS is defined as the time from the date of randomization until death due to ay cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.","populationDescription":"The PD-L1 TC \\>= 50% LREM analysis set included participants with PD-L1 TC \\>= 50% and identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 o 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"199"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","lowerLimit":"12.6","upperLimit":"19.0"},{"groupId":"OG001","value":"14.9","lowerLimit":"11.8","upperLimit":"17.7"}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) Based on Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"The PFS (per RECIST 1.1) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1). Progression of disease per RECIST 1.1, when either 1 of the criteria met: Target lesion (TL): at least a 20% increase in the sum of diameters of TLs, for reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Non-target lesion (NTL): Unequivocal progression of existing NTLs. It may be due to an important progression in 1 lesion only or in several lesions. In all cases the progression must be clinically significant for the physician to consider changing (or stopping) therapy. New lesions: the presence of 1 or more new lesions was assessed as progression.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months DCO 27 October 2022)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 o 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"334"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","lowerLimit":"4.2","upperLimit":"5.7"},{"groupId":"OG001","value":"4.8","lowerLimit":"4.3","upperLimit":"5.6"}]}]}]},{"type":"SECONDARY","title":"PFS Based on Investigator Assessment According to RECIST 1.1 in LREM Analysis Set","description":"The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).","populationDescription":"The PD-L1 TC \\>= 25% LREM analysis set included participants identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"271"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"4.4","upperLimit":"6.4"},{"groupId":"OG001","value":"5.6","lowerLimit":"4.8","upperLimit":"5.9"}]}]}]},{"type":"SECONDARY","title":"PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% Analysis Set","description":"The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).","populationDescription":"The PD-L1 TC \\>= 50% analysis set included the subset of participants in the FAS whose PD-L1 expression status was PD-L1 TC \\>= 50% as defined by the VENTANA PD-L1 (SP263) assay.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"246"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"4.7","upperLimit":"6.5"},{"groupId":"OG001","value":"4.5","lowerLimit":"4.2","upperLimit":"5.6"}]}]}]},{"type":"SECONDARY","title":"PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% LREM Analysis Set","description":"The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).","populationDescription":"The PD-L1 TC \\>= 50% LREM analysis set included participants with PD-L1 TC \\>= 50% and identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"199"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"5.3","upperLimit":"7.0"},{"groupId":"OG001","value":"5.5","lowerLimit":"4.2","upperLimit":"5.7"}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment","description":"ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions (TLs). Any pathological lymph nodes selected as TLs had a reduction in short axis to \\< 10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.","populationDescription":"The FAS included all randomized participants who had PD-L1 expression TC \\>= 25% with the VENTANA PD-L1 (SP263) assay.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"334"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","lowerLimit":"0.324","upperLimit":"0.430"},{"groupId":"OG001","value":"37.4","lowerLimit":"0.322","upperLimit":"0.429"}]}]}]},{"type":"SECONDARY","title":"ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 25% LREM Analysis Set","description":"ORR (per RECIST 1.1 using Investigator assessments)was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.","populationDescription":"The PD-L1 TC \\>= 25% LREM analysis set included participants identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"271"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.5","lowerLimit":"0.327","upperLimit":"0.445"},{"groupId":"OG001","value":"40.2","lowerLimit":"0.343","upperLimit":"0.463"}]}]}]},{"type":"SECONDARY","title":"ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% Analysis Set","description":"ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.","populationDescription":"The PD-L1 TC \\>= 50% analysis set included the subset of participants in the FAS whose PD-L1 expression status was PD-L1 TC \\>= 50% as defined by the VENTANA PD-L1 (SP263) assay.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"246"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","lowerLimit":"0.359","upperLimit":"0.485"},{"groupId":"OG001","value":"40.7","lowerLimit":"0.345","upperLimit":"0.471"}]}]}]},{"type":"SECONDARY","title":"ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% LREM Analysis Set","description":"ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.","populationDescription":"The PD-L1 TC \\>= 50% LREM analysis set included participants with PD-L1 TC \\>= 50% and identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 o 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"199"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","lowerLimit":"0.371","upperLimit":"0.510"},{"groupId":"OG001","value":"43.7","lowerLimit":"0.367","upperLimit":"0.509"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR) as Per RECIST 1.1 Using Investigator Assessment","description":"DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"125"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","lowerLimit":"9.7","upperLimit":"18.7"},{"groupId":"OG001","value":"4.2","lowerLimit":"3.3","upperLimit":"4.6"}]}]}]},{"type":"SECONDARY","title":"DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=25% LREM Analysis Set","description":"DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 TC \\>= 25% LREM analysis set included participants identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 o 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","lowerLimit":"8.2","upperLimit":"15.7"},{"groupId":"OG001","value":"4.2","lowerLimit":"4.0","upperLimit":"5.4"}]}]}]},{"type":"SECONDARY","title":"DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% Analysis Set","description":"DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 TC \\>= 50% analysis set included the subset of participants in the FAS whose PD-L1 expression status was PD-L1 TC \\>= 50% as defined by the VENTANA PD-L1 (SP263) assay.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","lowerLimit":"8.3","upperLimit":"21.2"},{"groupId":"OG001","value":"4.2","lowerLimit":"3.0","upperLimit":"4.6"}]}]}]},{"type":"SECONDARY","title":"DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% LREM Analysis Set","description":"DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 TC \\>= 50% LREM analysis set included participants with PD-L1 TC \\>= 50% and identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"87"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","lowerLimit":"8.2","upperLimit":"19.7"},{"groupId":"OG001","value":"4.2","lowerLimit":"3.9","upperLimit":"5.4"}]}]}]},{"type":"SECONDARY","title":"Alive and Progression-Free at 12 Months (APF12)","description":"The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of randomization until 12 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"334"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","lowerLimit":"20.8","upperLimit":"30.4"},{"groupId":"OG001","value":"13.3","lowerLimit":"9.6","upperLimit":"17.5"}]}]}]},{"type":"SECONDARY","title":"APF12 in PD-L1 TC >= 25% LREM Analysis Set","description":"The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.","populationDescription":"The PD-L1 TC \\>= 25% LREM analysis set included participants identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of randomization until 12 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"271"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","lowerLimit":"19.1","upperLimit":"29.5"},{"groupId":"OG001","value":"16.4","lowerLimit":"11.9","upperLimit":"21.5"}]}]}]},{"type":"SECONDARY","title":"APF12 in PD-L1 TC >= 50% Analysis Set","description":"The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.","populationDescription":"The PD-L1 TC \\>= 50% analysis set included the subset of participants in the FAS whose PD-L1 expression status was PD-L1 TC \\>= 50% as defined by the VENTANA PD-L1 (SP263) assay.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of randomization until 12 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"246"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","lowerLimit":"20.7","upperLimit":"31.9"},{"groupId":"OG001","value":"11.7","lowerLimit":"7.7","upperLimit":"16.5"}]}]}]},{"type":"SECONDARY","title":"APF12 in PD-L1 TC >= 50% LREM Analysis Set","description":"The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.","populationDescription":"The PD-L1 TC \\>= 50% LREM analysis set included participants with PD-L1 TC \\>= 50% and identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of randomization until 12 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"199"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","lowerLimit":"20.5","upperLimit":"32.8"},{"groupId":"OG001","value":"14.5","lowerLimit":"9.6","upperLimit":"20.4"}]}]}]},{"type":"SECONDARY","title":"Time From Randomization to Second Progression (PFS2)","description":"PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.","populationDescription":"The FAS included all randomized participants who had PD-L1 expression TC \\>= 25% with the VENTANA PD-L1 (SP263) assay.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"334"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","lowerLimit":"9.8","upperLimit":"12.7"},{"groupId":"OG001","value":"9.3","lowerLimit":"8.1","upperLimit":"10.7"}]}]}]},{"type":"SECONDARY","title":"PFS2 in PD-L1 TC >= 25% LREM Analysis Set","description":"PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 TC \\>= 25% LREM analysis set included participants identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"271"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","lowerLimit":"10.1","upperLimit":"12.9"},{"groupId":"OG001","value":"10.9","lowerLimit":"9.3","upperLimit":"13.1"}]}]}]},{"type":"SECONDARY","title":"PFS2 in PD-L1 TC >= 50% Analysis Set","description":"PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 TC \\>= 50% analysis set included the subset of participants in the FAS whose PD-L1 expression status was PD-L1 TC \\>= 50% as defined by the VENTANA PD-L1 (SP263) assay.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"246"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","lowerLimit":"9.7","upperLimit":"12.9"},{"groupId":"OG001","value":"8.8","lowerLimit":"8.0","upperLimit":"10.9"}]}]}]},{"type":"SECONDARY","title":"PFS2 in PD-L1 TC >= 50% LREM Analysis Set","description":"PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 TC \\>= 50% LREM analysis set included participants with PD-L1 TC \\>= 50% and identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"199"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","lowerLimit":"10.1","upperLimit":"13.8"},{"groupId":"OG001","value":"10.9","lowerLimit":"8.8","upperLimit":"13.1"}]}]}]},{"type":"SECONDARY","title":"OS at 18 Months","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of randomization till 18 months.","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"334"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.5","lowerLimit":"37.1","upperLimit":"47.7"},{"groupId":"OG001","value":"34.2","lowerLimit":"29.0","upperLimit":"39.4"}]}]}]},{"type":"SECONDARY","title":"OS at 18 Months in PD-L1 TC > = 25% LREM Analysis Set","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.","populationDescription":"The PD-L1 TC \\>= 25% LREM analysis set included participants identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of randomization till 18 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"271"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.0","lowerLimit":"37.1","upperLimit":"48.8"},{"groupId":"OG001","value":"41.4","lowerLimit":"35.4","upperLimit":"47.4"}]}]}]},{"type":"SECONDARY","title":"OS at 18 Months in PD-L1 TC >= 50% Analysis Set","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.","populationDescription":"The PD-L1 TC \\>= 50% analysis set included the subset of participants in the FAS whose PD-L1 expression status was PD-L1 TC \\>= 50% as defined by the VENTANA PD-L1 (SP263) assay.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of randomization till 18 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"246"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","lowerLimit":"36.9","upperLimit":"49.3"},{"groupId":"OG001","value":"34.9","lowerLimit":"28.8","upperLimit":"41.0"}]}]}]},{"type":"SECONDARY","title":"OS at 18 Months in PD-L1 TC >= 50% LREM Analysis Set","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.","populationDescription":"The PD-L1 TC \\>= 50% LREM analysis set included participants with PD-L1 TC \\>= 50% and identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of randomization till 18 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"199"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3","lowerLimit":"37.4","upperLimit":"51.0"},{"groupId":"OG001","value":"42.2","lowerLimit":"35.2","upperLimit":"49.1"}]}]}]},{"type":"SECONDARY","title":"OS at 24 Months","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of randomization till 24 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"334"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.6","lowerLimit":"29.5","upperLimit":"39.7"},{"groupId":"OG001","value":"27.2","lowerLimit":"22.4","upperLimit":"32.1"}]}]}]},{"type":"SECONDARY","title":"OS at 24 Months in PD-L1 TC > = 25% LREM Analysis Set","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.","populationDescription":"The PD-L1 TC \\>= 25% LREM analysis set included participants identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of randomization till 24 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"271"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","lowerLimit":"29.1","upperLimit":"40.3"},{"groupId":"OG001","value":"32.8","lowerLimit":"27.2","upperLimit":"38.6"}]}]}]},{"type":"SECONDARY","title":"OS at 24 Months in PD-L1 TC >= 50% Analysis Set","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.","populationDescription":"The PD-L1 TC \\>= 50% analysis set included the subset of participants in the FAS whose PD-L1 expression status was PD-L1 TC \\>= 50% as defined by the VENTANA PD-L1 (SP263) assay.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of randomization till 24 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"246"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.0","lowerLimit":"31.0","upperLimit":"43.1"},{"groupId":"OG001","value":"27.0","lowerLimit":"21.5","upperLimit":"32.8"}]}]}]},{"type":"SECONDARY","title":"OS at 24 Months in PD-L1 TC >= 50% LREM Analysis Set","description":"OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.","populationDescription":"The PD-L1 TC \\>= 50% LREM analysis set included participants with PD-L1 TC \\>= 50% and identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of randomization till 24 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"199"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.9","lowerLimit":"30.3","upperLimit":"43.5"},{"groupId":"OG001","value":"32.6","lowerLimit":"26.1","upperLimit":"39.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire Version 3 (QLQ-C30)","description":"The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual. An outcome variable consisted of a score from 0 to 100. Higher scores on the global health status and functioning scales indicate better health status/function, but higher scores on symptom scales/items represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The mixed model repeated measures (MMRM) analysis of EORTC QLQ-C30 considered all data from baseline to PD or 12 months.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline and 12 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"249"}]}],"classes":[{"title":"Global health status","categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.19"},{"groupId":"OG001","value":"-7.4","spread":"1.27"}]}]},{"title":"Physical functioning","categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"1.23"},{"groupId":"OG001","value":"-6.1","spread":"1.30"}]}]},{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.33"},{"groupId":"OG001","value":"7.2","spread":"1.43"}]}]},{"title":"Appetite loss","categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.39"},{"groupId":"OG001","value":"9.1","spread":"1.50"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set","description":"The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual. An outcome variable consisted of a score from 0 to 100. Higher scores on the global health status and functioning scales indicate better health status/function, but higher scores on symptom scales/items represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-C30 considered all data from baseline to PD or 12 months.","populationDescription":"The PD-L1 TC \\>= 25% LREM analysis set included participants identified by a prognostic model developed by AstraZeneca as having LREM. Only data from the participants analyzed were reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline and 12 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"236"},{"groupId":"OG001","value":"208"}]}],"classes":[{"title":"Global health status","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"1.23"},{"groupId":"OG001","value":"-7.3","spread":"1.31"}]}]},{"title":"Physical functioning","categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"1.22"},{"groupId":"OG001","value":"-6.0","spread":"1.29"}]}]},{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.33"},{"groupId":"OG001","value":"7.7","spread":"1.42"}]}]},{"title":"Appetite loss","categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.43"},{"groupId":"OG001","value":"9.8","spread":"1.52"}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration of EORTC QLQ-C30","description":"Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful deterioration (a decrease in the function scales or the global health status/ health-related quality of life \\[HRQoL\\] from baseline of ≥10) that was confirmed at a subsequent visit or death in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual.","populationDescription":"The FAS included all randomized participants. Only data from the participants analyzed were reported.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization until date of first symptom deterioration that is confirmed, assessed up to a maximum of approximately 69 months (DCO 27 October 2022)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"291"}]}],"classes":[{"title":"Global health status","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"288"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","lowerLimit":"5.5","upperLimit":"9.1"},{"groupId":"OG001","value":"3.8","lowerLimit":"3.6","upperLimit":"5.5"}]}]},{"title":"Physical functioning","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"291"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","lowerLimit":"5.6","upperLimit":"9.8"},{"groupId":"OG001","value":"3.8","lowerLimit":"3.6","upperLimit":"5.2"}]}]},{"title":"Appetite loss","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","lowerLimit":"7.3","upperLimit":"11.4"},{"groupId":"OG001","value":"3.6","lowerLimit":"2.3","upperLimit":"3.8"}]}]},{"title":"Fatigue","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"289"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","lowerLimit":"3.7","upperLimit":"7.0"},{"groupId":"OG001","value":"1.8","lowerLimit":"1.6","upperLimit":"2.6"}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration of EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set","description":"Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual.","populationDescription":"The PD-L1 TC \\>= 25% LREM analysis set included participants identified by a prognostic model developed by AstraZeneca as having LREM. Only data from the participants analyzed were reported.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization until date of first symptom deterioration that is confirmed, assessed up to a maximum of approximately 69 months (DCO 27 October 2022)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"239"}]}],"classes":[{"title":"Global health status","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"238"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","lowerLimit":"5.6","upperLimit":"9.2"},{"groupId":"OG001","value":"5.5","lowerLimit":"3.7","upperLimit":"6.5"}]}]},{"title":"Physical functioning","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"239"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","lowerLimit":"5.6","upperLimit":"10.1"},{"groupId":"OG001","value":"4.7","lowerLimit":"3.7","upperLimit":"5.8"}]}]},{"title":"Appetite loss","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"233"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","lowerLimit":"7.3","upperLimit":"11.6"},{"groupId":"OG001","value":"3.7","lowerLimit":"2.6","upperLimit":"5.0"}]}]},{"title":"Fatigue","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"237"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"3.8","upperLimit":"7.4"},{"groupId":"OG001","value":"1.8","lowerLimit":"1.6","upperLimit":"3.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EORTC 13-Item Lung Cancer Quality of Life Questionnaire (QLQ-LC13)","description":"The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication. An outcome variable consisted of a score from 0 to 100. Higher scores on symptom scales represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-LC13 considered all data from baseline to PD or 12 months.","populationDescription":"The FAS included all randomized participants. Only data from the participants analyzed were reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline and 12 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"274"},{"groupId":"OG001","value":"259"}]}],"classes":[{"title":"Cough","categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"1.30"},{"groupId":"OG001","value":"-7.9","spread":"1.41"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.24"},{"groupId":"OG001","value":"4.1","spread":"1.32"}]}]},{"title":"Chest pain","categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.26"},{"groupId":"OG001","value":"-0.2","spread":"1.37"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set","description":"The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication. An outcome variable consisted of a score from 0 to 100. Higher scores on symptom scales represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-LC13 considered all data from baseline to PD or 12 months.","populationDescription":"The PD-L1 TC \\>= 25% LREM analysis set included participants identified by a prognostic model developed by AstraZeneca as having LREM. Only data from the participants analyzed were reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline and 12 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"216"}]}],"classes":[{"title":"Cough","categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"1.38"},{"groupId":"OG001","value":"-8.6","spread":"1.48"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"1.28"},{"groupId":"OG001","value":"3.9","spread":"1.35"}]}]},{"title":"Chest pain","categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.30"},{"groupId":"OG001","value":"-1.0","spread":"1.40"}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration of EORTC QLQ-LC13","description":"Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful symptom deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication.","populationDescription":"The FAS included all randomized participants. Only data from the participants analyzed were reported.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization until date of first symptom deterioration that is confirmed, assessed up to maximum of approximately 69 months (DCO 27 October 2022)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"281"}]}],"classes":[{"title":"Cough","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"276"},{"groupId":"OG001","value":"272"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","lowerLimit":"6.4","upperLimit":"10.1"},{"groupId":"OG001","value":"6.6","lowerLimit":"5.6","upperLimit":"8.2"}]}]},{"title":"Dyspnea","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"281"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"1.9","upperLimit":"4.6"},{"groupId":"OG001","value":"3.6","lowerLimit":"2.4","upperLimit":"3.8"}]}]},{"title":"Chest pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","lowerLimit":"6.3","upperLimit":"11.9"},{"groupId":"OG001","value":"6.4","lowerLimit":"4.6","upperLimit":"7.2"}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration of EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set","description":"Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful symptom deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication.","populationDescription":"The PD-L1 TC \\>= 25% LREM analysis set included participants identified by a prognostic model developed by AstraZeneca as having LREM. Only data from the participants analyzed were reported.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization until date of first symptom deterioration that is confirmed, assessed up to maximum of approximately 69 months (DCO 27 October 2022)","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"233"}]}],"classes":[{"title":"Cough","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"225"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","lowerLimit":"6.4","upperLimit":"12.3"},{"groupId":"OG001","value":"8.2","lowerLimit":"6.4","upperLimit":"11.1"}]}]},{"title":"Dyspnea","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"233"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","lowerLimit":"2.0","upperLimit":"4.7"},{"groupId":"OG001","value":"3.6","lowerLimit":"2.4","upperLimit":"3.8"}]}]},{"title":"Chest pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"242"},{"groupId":"OG001","value":"231"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","lowerLimit":"6.4","upperLimit":"12.6"},{"groupId":"OG001","value":"6.6","lowerLimit":"5.8","upperLimit":"9.2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"ECOG performance status was assessed at the times specified based on the following and scored as 0: fully active: able to carry out all usual activities without restrictions. 1: Restricted in strenuous activity, but ambulatory and able to carry out any work activities; up and about more than 50% of waking hours. 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 4: Completely disabled; unable to carry out any self-care and totally confined to bed or chair and 5: death. Data for only participants with restricted activity has been reported.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of participants","timeFrame":"From Baseline and until follow-up period of 57 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2.\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"334"}]}],"classes":[{"title":"Restricted activity, Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"267"},{"groupId":"OG001","value":"255"}]}]},{"title":"Restricted activity, Follow-up Month 57","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With ECOG Performance Status in PD-L1 TC >=25% LREM Analysis Set","description":"ECOG performance status was assessed at the times specified based on the following and scored as 0: fully active: able to carry out all usual activities without restrictions. 1: Restricted in strenuous activity, but ambulatory and able to carry out any work activities; up and about more than 50% of waking hours. 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 4: Completely disabled; unable to carry out any self-care and totally confined to bed or chair and 5: death. Data for only participants with restricted activity has been reported.","populationDescription":"The PD-L1 TC \\>= 25% LREM analysis set included participants identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of participants","timeFrame":"From Baseline and until follow-up period of 57 months","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"271"}]}],"classes":[{"title":"Restricted activity, Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"203"}]}]},{"title":"Restricted activity, Follow-up Month 57","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Antidrug Antibody (ADA) Response to Durvalumab","description":"Treatment-emergent ADA positive was defined as either treatment-induced or treatment-boosted ADA. Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following study drug administration. Persistently positive was defined as positive at least 2 post-baseline assessments with at least 16 weeks between the first and last positive assessment or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.","populationDescription":"The ADA evaluable analysis set included all participants in the safety analysis set who had a non-missing baseline ADA and at least 1 non-missing post-baseline ADA result.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Up to 24 weeks","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"236"}]}],"classes":[{"title":"Treatment-emergent ADA positive","categories":[{"measurements":[{"groupId":"OG000","value":"0.8"}]}]},{"title":"Treatment-boosted ADA","categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}]},{"title":"Persistently positive","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Transiently positive","categories":[{"measurements":[{"groupId":"OG000","value":"0.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ADA Response to Durvalumab in LREM Analysis Set","description":"Treatment-emergent ADA positive was defined as either treatment-induced or treatment-boosted ADA. Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following study drug administration. Persistently positive was defined as positive at least 2 post-baseline assessments with at least 16 weeks between the first and last positive assessment or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.","populationDescription":"The ADA evaluable LREM analysis set included all participants in the safety analysis set who had a non-missing baseline ADA and at least 1 non-missing post-baseline ADA result, and identified by a prognostic model developed by AstraZeneca as having LREM.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Up to 24 weeks","groups":[{"id":"OG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"208"}]}],"classes":[{"title":"Treatment-emergent ADA positive","categories":[{"measurements":[{"groupId":"OG000","value":"1.0"}]}]},{"title":"Treatment-boosted ADA","categories":[{"measurements":[{"groupId":"OG000","value":"0.5"}]}]},{"title":"Persistently positive","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Transiently positive","categories":[{"measurements":[{"groupId":"OG000","value":"1.0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From first administration of study treatment up to 90 days after the last dose of durvalumab or 30 days after last dose of platinum based SoC or date of initiation of the first subsequent therapy, whichever occurs first, for approximately 69 months.","description":"The Safety analysis set included all participants who received at least 1 dose of study treatment. All-cause mortality was in FAS analysis set.","eventGroups":[{"id":"EG000","title":"Durvalumab","description":"Participants received durvalumab 20 mg/kg via IV infusion Q4W until documented PD or unacceptable toxicity or until specific treatment discontinuation criteria were met.","deathsNumAffected":274,"deathsNumAtRisk":335,"seriousNumAffected":132,"seriousNumAtRisk":335,"otherNumAffected":271,"otherNumAtRisk":335},{"id":"EG001","title":"Platinum-based SoC","description":"Participants received 1 of the following IV infusion treatment combination platinum-based SoC as per Investigator's choice on Day 1 of each 21-day cycle for 4 to 6 cycles or until documented PD or until specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2 (for squamous participants).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 via infusions (for squamous participants).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (for non-squamous participants; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 via IV infusions (for non-squamous participants; pemetrexed maintenance dose was permitted).","deathsNumAffected":277,"deathsNumAtRisk":334,"seriousNumAffected":104,"seriousNumAtRisk":327,"otherNumAffected":294,"otherNumAtRisk":327}],"seriousEvents":[{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Leukaemoid reaction","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":327}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":327}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":327}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":327}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":327}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":327}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Complicated appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Gastroenteritis shigella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Myelosuppression","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":16,"numAffected":14,"numAtRisk":327}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":327}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Infusion site cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":335},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":327}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":327}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":26,"numAtRisk":335},{"groupId":"EG001","numEvents":18,"numAffected":17,"numAtRisk":327}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":327}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":335},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":327}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Nervous system injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":327}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Coagulation time abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Coagulopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Neutrophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":327}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":327}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Cachexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Cardiogenic shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Osteonecrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Osteonecrosis of jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Synovitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Adenocarcinoma of colon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Immune-mediated myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Gastric cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Metastases to heart","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Tumour thrombosis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Bell's palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Cerebral artery embolism","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":335},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":327}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Demyelination","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Diplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Immune-mediated encephalitis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Noninfective encephalitis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Parkinson's disease","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Vocal cord paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Neurosis","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Pericardial haemorrhage","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Disseminated intravascular coagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Calculus prostatic","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Orchitis noninfective","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Bronchial obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":335},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":327}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":335},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":327}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":335},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":327}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Acute generalised exanthematous pustulosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Circulatory collapse","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Ventricular pre-excitation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Deafness neurosensory","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Peripheral embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Hypophysitis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Thyroiditis subacute","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":327}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":327}]},{"term":"Anal fissure","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":327}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":28,"numAtRisk":335},{"groupId":"EG001","numEvents":200,"numAffected":107,"numAtRisk":327}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":1,"numAtRisk":335},{"groupId":"EG001","numEvents":135,"numAffected":51,"numAtRisk":327}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":17,"numAtRisk":335},{"groupId":"EG001","numEvents":97,"numAffected":59,"numAtRisk":327}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":37,"numAtRisk":335},{"groupId":"EG001","numEvents":66,"numAffected":39,"numAtRisk":327}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":22,"numAtRisk":335},{"groupId":"EG001","numEvents":38,"numAffected":30,"numAtRisk":327}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":17,"numAtRisk":335},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":327}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":82,"numAffected":46,"numAtRisk":335},{"groupId":"EG001","numEvents":33,"numAffected":25,"numAtRisk":327}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":23,"numAtRisk":335},{"groupId":"EG001","numEvents":25,"numAffected":17,"numAtRisk":327}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":111,"numAffected":81,"numAtRisk":335},{"groupId":"EG001","numEvents":266,"numAffected":168,"numAtRisk":327}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":335},{"groupId":"EG001","numEvents":134,"numAffected":54,"numAtRisk":327}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":27,"numAtRisk":335},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":327}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":335},{"groupId":"EG001","numEvents":67,"numAffected":34,"numAtRisk":327}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":55,"numAffected":33,"numAtRisk":335},{"groupId":"EG001","numEvents":22,"numAffected":20,"numAtRisk":327}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":29,"numAtRisk":335},{"groupId":"EG001","numEvents":75,"numAffected":45,"numAtRisk":327}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":21,"numAtRisk":335},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":327}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":27,"numAtRisk":335},{"groupId":"EG001","numEvents":62,"numAffected":38,"numAtRisk":327}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":15,"numAtRisk":335},{"groupId":"EG001","numEvents":24,"numAffected":19,"numAtRisk":327}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":8,"numAtRisk":335},{"groupId":"EG001","numEvents":23,"numAffected":17,"numAtRisk":327}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":9,"numAtRisk":335},{"groupId":"EG001","numEvents":251,"numAffected":85,"numAtRisk":327}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":15,"numAtRisk":335},{"groupId":"EG001","numEvents":129,"numAffected":56,"numAtRisk":327}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":46,"numAtRisk":335},{"groupId":"EG001","numEvents":26,"numAffected":26,"numAtRisk":327}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":21,"numAtRisk":335},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":327}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":13,"numAtRisk":335},{"groupId":"EG001","numEvents":291,"numAffected":84,"numAtRisk":327}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":80,"numAffected":66,"numAtRisk":335},{"groupId":"EG001","numEvents":178,"numAffected":94,"numAtRisk":327}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":37,"numAtRisk":335},{"groupId":"EG001","numEvents":21,"numAffected":18,"numAtRisk":327}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":24,"numAtRisk":335},{"groupId":"EG001","numEvents":29,"numAffected":26,"numAtRisk":327}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":29,"numAtRisk":335},{"groupId":"EG001","numEvents":27,"numAffected":24,"numAtRisk":327}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":335},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":327}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":335},{"groupId":"EG001","numEvents":25,"numAffected":21,"numAtRisk":327}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":335},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":327}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":24,"numAtRisk":335},{"groupId":"EG001","numEvents":26,"numAffected":24,"numAtRisk":327}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":29,"numAtRisk":335},{"groupId":"EG001","numEvents":17,"numAffected":16,"numAtRisk":327}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":19,"numAtRisk":335},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":327}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":17,"numAtRisk":335},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":327}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":335},{"groupId":"EG001","numEvents":42,"numAffected":42,"numAtRisk":327}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":18,"numAtRisk":335},{"groupId":"EG001","numEvents":10,"numAffected":6,"numAtRisk":327}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":29,"numAtRisk":335},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":327}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":20,"numAtRisk":335},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":327}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":24,"numAtRisk":335},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":327}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":85,"numAffected":50,"numAtRisk":335},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":327}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":32,"numAtRisk":335},{"groupId":"EG001","numEvents":85,"numAffected":57,"numAtRisk":327}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":23,"numAtRisk":335},{"groupId":"EG001","numEvents":30,"numAffected":26,"numAtRisk":327}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"title":"Global Clinical Lead","organization":"AstraZeneca","email":"information.center@astrazeneca.com","phone":"1-877-240-9479"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-06-18","uploadDate":"2023-10-23T01:53","filename":"Prot_000.pdf","size":4494707},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2021-06-11","uploadDate":"2023-10-23T01:53","filename":"SAP_001.pdf","size":2765738}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"interventionBrowseModule":{"meshes":[{"id":"C000613593","term":"durvalumab"},{"id":"C053518","term":"CP protocol"},{"id":"D000093542","term":"Gemcitabine"},{"id":"D002945","term":"Cisplatin"},{"id":"D016190","term":"Carboplatin"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}